Pharmacokinetically-guided on the Individualization of Pembrolizumab Administration in the Treatment of Lung Cancer
Status:
Completed
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Pembrolizumab with or without chemotherapy has become the standard therapy in advanced
non-small cell lung cancer (NSCLC), with a fixed dose of 200mg every 3 weeks. The
investigators performed this study to explore the clinical efficacy and safety of
pharmacokinetic (PK)-guided pembrolizumab administration in advanced NSCLC.